Logo image of CY4.MI

CY4GATE SPA (CY4.MI) Stock Fundamental Analysis

BIT:CY4 - Euronext Milan - IT0005412504 - Common Stock - Currency: EUR

4.52  +0.29 (+6.98%)

Fundamental Rating

3

Taking everything into account, CY4 scores 3 out of 10 in our fundamental rating. CY4 was compared to 101 industry peers in the Software industry. The financial health of CY4 is average, but there are quite some concerns on its profitability. CY4 is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year CY4 has reported negative net income.
In the past year CY4 had a positive cash flow from operations.
CY4 had positive earnings in 4 of the past 5 years.
The reported operating cash flow has been mixed in the past 5 years: CY4 reported negative operating cash flow in multiple years.
CY4.MI Yearly Net Income VS EBIT VS OCF VS FCFCY4.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M

1.2 Ratios

With a Return On Assets value of -14.75%, CY4 is not doing good in the industry: 75.76% of the companies in the same industry are doing better.
CY4 has a worse Return On Equity (-28.80%) than 70.71% of its industry peers.
Industry RankSector Rank
ROA -14.75%
ROE -28.8%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CY4.MI Yearly ROA, ROE, ROICCY4.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 -50 -100 -150 -200

1.3 Margins

Looking at the Gross Margin, with a value of 49.73%, CY4 is doing worse than 68.69% of the companies in the same industry.
CY4's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for CY4 so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 49.73%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.94%
GM growth 5Y50.92%
CY4.MI Yearly Profit, Operating, Gross MarginsCY4.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 0 50 -50

More info and screens

4

2. Health

2.1 Basic Checks

CY4 does not have a ROIC to compare to the WACC, probably because it is not profitable.
CY4 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CY4.MI Yearly Shares OutstandingCY4.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 5M 10M 15M 20M
CY4.MI Yearly Total Debt VS Total AssetsCY4.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

2.2 Solvency

CY4 has an Altman-Z score of 0.94. This is a bad value and indicates that CY4 is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.94, CY4 is doing worse than 68.69% of the companies in the same industry.
The Debt to FCF ratio of CY4 is 2.17, which is a good value as it means it would take CY4, 2.17 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of CY4 (2.17) is better than 66.67% of its industry peers.
CY4 has a Debt/Equity ratio of 0.36. This is a healthy value indicating a solid balance between debt and equity.
CY4 has a Debt to Equity ratio of 0.36. This is comparable to the rest of the industry: CY4 outperforms 41.41% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF 2.17
Altman-Z 0.94
ROIC/WACCN/A
WACC8.69%
CY4.MI Yearly LT Debt VS Equity VS FCFCY4.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 20M 40M 60M 80M 100M

2.3 Liquidity

A Current Ratio of 1.86 indicates that CY4 should not have too much problems paying its short term obligations.
CY4 has a Current ratio of 1.86. This is in the better half of the industry: CY4 outperforms 73.74% of its industry peers.
CY4 has a Quick Ratio of 1.84. This is a normal value and indicates that CY4 is financially healthy and should not expect problems in meeting its short term obligations.
With a decent Quick ratio value of 1.84, CY4 is doing good in the industry, outperforming 72.73% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.86
Quick Ratio 1.84
CY4.MI Yearly Current Assets VS Current LiabilitesCY4.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for CY4 have decreased strongly by -588.90% in the last year.
The Revenue has grown by 22.99% in the past year. This is a very strong growth!
CY4 shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 66.46% yearly.
EPS 1Y (TTM)-588.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.94%
Revenue 1Y (TTM)22.99%
Revenue growth 3Y74.28%
Revenue growth 5Y66.46%
Sales Q2Q%47.6%

3.2 Future

The Earnings Per Share is expected to grow by 32.94% on average over the next years. This is a very strong growth
Based on estimates for the next years, CY4 will show a quite strong growth in Revenue. The Revenue will grow by 12.06% on average per year.
EPS Next Y17.38%
EPS Next 2Y38.16%
EPS Next 3Y32.94%
EPS Next 5YN/A
Revenue Next Year16.87%
Revenue Next 2Y13.83%
Revenue Next 3Y12.06%
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
CY4.MI Yearly Revenue VS EstimatesCY4.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 20M 40M 60M 80M
CY4.MI Yearly EPS VS EstimatesCY4.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 0.2 -0.2

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

CY4 reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CY4. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CY4.MI Price Earnings VS Forward Price EarningsCY4.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -50 -100 -150

4.2 Price Multiples

98.99% of the companies in the same industry are more expensive than CY4, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 4.84
EV/EBITDA N/A
CY4.MI Per share dataCY4.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3 4

4.3 Compensation for Growth

CY4's earnings are expected to grow with 32.94% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.16%
EPS Next 3Y32.94%

More info and screens

0

5. Dividend

5.1 Amount

CY4 does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CY4GATE SPA

BIT:CY4 (3/7/2025, 7:00:00 PM)

4.52

+0.29 (+6.98%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSoftware & Services
GICS IndustrySoftware
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners13.64%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap106.54M
Analysts86.67
Price Target6.48 (43.36%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP-3.72%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-6.62%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-272.39%
EPS NY rev (3m)-701.2%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-5.35%
Revenue NY rev (3m)-5.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.21
P/FCF 4.84
P/OCF 3.95
P/B 1.1
P/tB 8.35
EV/EBITDA N/A
EPS(TTM)-1.14
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)0.93
FCFY20.65%
OCF(TTM)1.14
OCFY25.31%
SpS3.74
BVpS4.1
TBVpS0.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.75%
ROE -28.8%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 49.73%
FCFM 24.95%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.94%
GM growth 5Y50.92%
F-Score3
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0.36
Debt/FCF 2.17
Debt/EBITDA N/A
Cap/Depr 28.09%
Cap/Sales 5.64%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.86
Quick Ratio 1.84
Altman-Z 0.94
F-Score3
WACC8.69%
ROIC/WACCN/A
Cap/Depr(3y)17.19%
Cap/Depr(5y)62.53%
Cap/Sales(3y)3.95%
Cap/Sales(5y)7.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-588.9%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.94%
EPS Next Y17.38%
EPS Next 2Y38.16%
EPS Next 3Y32.94%
EPS Next 5YN/A
Revenue 1Y (TTM)22.99%
Revenue growth 3Y74.28%
Revenue growth 5Y66.46%
Sales Q2Q%47.6%
Revenue Next Year16.87%
Revenue Next 2Y13.83%
Revenue Next 3Y12.06%
Revenue Next 5YN/A
EBIT growth 1Y-3687.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year624.39%
EBIT Next 3Y107.92%
EBIT Next 5YN/A
FCF growth 1Y1156.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2178.38%
OCF growth 3YN/A
OCF growth 5YN/A